Quantity of Toxin in Stool Correlates with C. difficile Severity
By LabMedica International staff writers Posted on 25 Oct 2021 |
Image: Colored Transmission electron micrograph of Clostridium difficile bacterium forming an endospore (lower right, red oval). Clostridium difficile produce a toxin that irritates the colon and causes diarrhea (Photo courtesy of Kari Lounatmaa, PhD)
Clostridioides difficile (syn. Clostridium difficile), also known as C. difficile, or C. diff are Gram-positive species of spore-forming bacteria. Clostridioides spp. are anaerobic, motile bacteria, ubiquitous in nature and especially prevalent in soil. C. difficile cells are Gram-positive and show optimum growth on blood agar at human body temperatures in the absence of oxygen.
Although C. difficile is commonly known as a hospital and antibiotic associated pathogen, at most one third of infections can be traced to transmission from an infected person in hospitals, and only a small number of antibiotics are directly associated with an elevated risk of developing a C. difficile infection (CDI). Pathogenic C. difficile strains produce multiple toxins.
Infectious Disease Specialists at the Beth Israel Deaconess Medical Center (Boston, MA, USA) and their colleagues enrolled 615 hospitalized adults (≥ 18 years) with CDI (acute diarrhea, positive stool Nucleic Acid Amplification Test (NAAT), and decision to treat). Baseline stool toxin A and B concentrations were measured by Simoa Single Molecule Array (Quanterix, Billerica, MA, USA). Subjects were classified by baseline CDI severity (four scoring methods) and outcomes within 40 days (death, ICU stay, colectomy, and recurrence).
The investigators reported that overall, the study showed that across all scoring systems, patients with severe baseline disease had higher stool toxin A and B concentrations than those without. Nineteen subjects (3.1%) had a severe outcome primarily-attributed to CDI (group 1). This group had higher median toxin A+B (14,303 pg/mL) than subjects in whom CDI only contributed to the outcome (group 2, 163.2 pg/mL), subjects with severe outcome unrelated to CDI (group 3, 158.6 pg/mL), or no severe outcome (group 4, 209.5 pg/mL). Group 1 was more likely to have detectable toxin (94.7%) than groups 2-4 (60.5%-66.1%). Individuals with recurrence had higher toxin A+B (2,266.8 pg/mL) than those without (154.0 pg/mL) and higher rates of detectable toxin (85.7% versus 64.0%).
Carolyn D. Alonso, MD, an Assistant Professor of Medicine and first author of the study, and her colleagues said, “This study lays the foundation for developing a highly accurate, single-step test to better diagnose C. difficile infection and predict clinical outcomes. Ultimately, we hope that our research will move the field toward development of a single-step test for C. difficile that can be easily deployed by clinicians without specific expertise in C. difficile diagnosis.”
The authors concluded that in CDI patients, ultrasensitive stool toxin detection and concentration correlated with severe baseline disease, severe CDI-attributable outcomes, and recurrence, confirming the contribution of toxin quantity to disease presentation and clinical course. The study was published on September 19, 2021 in the journal Clinical Infectious Diseases.
Related Links:
Beth Israel Deaconess Medical Center
Quanterix
Although C. difficile is commonly known as a hospital and antibiotic associated pathogen, at most one third of infections can be traced to transmission from an infected person in hospitals, and only a small number of antibiotics are directly associated with an elevated risk of developing a C. difficile infection (CDI). Pathogenic C. difficile strains produce multiple toxins.
Infectious Disease Specialists at the Beth Israel Deaconess Medical Center (Boston, MA, USA) and their colleagues enrolled 615 hospitalized adults (≥ 18 years) with CDI (acute diarrhea, positive stool Nucleic Acid Amplification Test (NAAT), and decision to treat). Baseline stool toxin A and B concentrations were measured by Simoa Single Molecule Array (Quanterix, Billerica, MA, USA). Subjects were classified by baseline CDI severity (four scoring methods) and outcomes within 40 days (death, ICU stay, colectomy, and recurrence).
The investigators reported that overall, the study showed that across all scoring systems, patients with severe baseline disease had higher stool toxin A and B concentrations than those without. Nineteen subjects (3.1%) had a severe outcome primarily-attributed to CDI (group 1). This group had higher median toxin A+B (14,303 pg/mL) than subjects in whom CDI only contributed to the outcome (group 2, 163.2 pg/mL), subjects with severe outcome unrelated to CDI (group 3, 158.6 pg/mL), or no severe outcome (group 4, 209.5 pg/mL). Group 1 was more likely to have detectable toxin (94.7%) than groups 2-4 (60.5%-66.1%). Individuals with recurrence had higher toxin A+B (2,266.8 pg/mL) than those without (154.0 pg/mL) and higher rates of detectable toxin (85.7% versus 64.0%).
Carolyn D. Alonso, MD, an Assistant Professor of Medicine and first author of the study, and her colleagues said, “This study lays the foundation for developing a highly accurate, single-step test to better diagnose C. difficile infection and predict clinical outcomes. Ultimately, we hope that our research will move the field toward development of a single-step test for C. difficile that can be easily deployed by clinicians without specific expertise in C. difficile diagnosis.”
The authors concluded that in CDI patients, ultrasensitive stool toxin detection and concentration correlated with severe baseline disease, severe CDI-attributable outcomes, and recurrence, confirming the contribution of toxin quantity to disease presentation and clinical course. The study was published on September 19, 2021 in the journal Clinical Infectious Diseases.
Related Links:
Beth Israel Deaconess Medical Center
Quanterix
Latest Microbiology News
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA
- Rapid Sepsis Test Delivers Two Days Faster Results
- Portable Rapid PCR Diagnostic to Detect Gonorrhea and Antibiotic Susceptibility